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Abstract
Introduction Ventral hernias are common and repair with
mesh has been shown to reduce recurrence. However,
synthetic mesh is associated with a risk of infection. Bio-
logic mesh is an alternative that may be less susceptible to
infection. Typically, the sublay position is preferred for
mesh placement but this technique takes longer and has not
been shown to have a lower recurrence rate than an onlay
mesh. The aim of this study was to evaluate the outcome of
complex ventral hernia repair using a porcine non-cross-
linked biologic mesh onlay.
Methods A retrospective chart review was performed of
all patients that had a ventral hernia repair with biologic
mesh from January 2009 to March 2012. The operative
procedure in all patients was an open repair with primary
fascial closure (if possible) with or without external obli-
que component separation and porcine biologic mesh
onlay.
Results There were 22 patients that had a ventral hernia
repair, 19 primary and 3 recurrent. The majority were men,
had hernia grade 3 or 4, and developed the hernia after an
esophagectomy or gastrectomy for cancer. All but one had
primary closure with a porcine biologic mesh onlay. One
patient was bridged for loss of domain. A bilateral external
oblique component separation was added in 16 patients
(73 %). The median hospital stay was 7 days. There were
two superficial wound infections, one with exposed mesh,
but no patient required mesh removal. A seroma requiring
intervention developed in 6 patients (27 %) and resolved
with pig-tail drainage. At a median follow-up of 7 months,
there has been no hernia recurrence apart from the patient
that was bridged.
Conclusions Porcine non-cross-linked biologic mesh
overlay has excellent short-term results in patients at
increased risk for mesh infection. No patient required mesh
removal, and there have been no recurrent hernias in
patients with primary fascial closure. Biologic bridging is
not effective for long-term abdominal wall reconstruction.
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Introduction
There are 4–5 million laparotomies performed in the Uni-
ted States annually, and an incisional hernia will develop in
10–15 % of these patients [1]. Ventral hernia repair is a
common procedure, with some 250,000 procedures per-
formed annually, but recurrence rates are high and increase
with each subsequent attempt at repair [2, 3]. The use of
synthetic mesh has been shown in a randomized prospec-
tive trial to reduce recurrence after ventral hernia repair [4].
However, synthetic mesh is associated with a number of
potential complications including erosion, fistula forma-
tion, and infection. One of the leading causes of a recurrent
hernia is infection, and the risk of infection is increased in
patients with a history of prior wound infection, emphy-
sema, diabetes, obesity and in those taking steroids or
smoking cigarettes [5]. These comorbid conditions are
common in patients with a ventral hernia and may be a
reason to consider use of a non-synthetic mesh.
E. T. Alicuben  S. R. DeMeester (&)
Department of Surgery, Keck School of Medicine,
The University of Southern California, 1510 San Pablo St,





An alternative to synthetic material is a biologic mesh.
One potential advantage of biologic mesh is that it may be
less susceptible to contamination and infection. However,
there is little data on the efficacy of biologic mesh for
ventral hernia repair. Our ventral hernia patient population
consists primarily of patients that had a laparotomy for
esophageal or gastric cancer. Most were in follow-up for
their cancer, and at risk for recurrent disease at the time the
ventral hernia was diagnosed. Since recurrence is generally
treated with chemotherapy, an indolent or active mesh
infection related to ventral hernia repair would compromise
the treatment options. The aim of this study was to review
our results for repair of complicated ventral hernias with a
porcine non-cross-linked biologic mesh onlay.
Methods
A retrospective chart review was performed of all patients
who underwent ventral hernia repair with use of a biologic
mesh from January 2009 to March 2012 by a single sur-
geon. The risk of infection was assessed using the hernia
grade system as described by the ventral hernia working
group [5]. In addition, at the time of the ventral hernia
repair, wounds were classified into one of the three cate-
gories: clean, clean–contaminated (exposure to gastroin-
testinal tract without spillage or necrosis), or contaminated
(hollow-viscous necrosis or gastrointestinal tract spillage).
Postoperatively, patients were seen at routine intervals, and
an abdominal examination was performed to evaluate the
integrity of the repair. Patients undergoing cancer follow-
up had abdominal CT scans every 3–6 months and these
were reviewed for both cancer recurrence and the status of
the ventral hernia repair. This study was approved by the
IRB of the University of Southern California.
The operative procedure in all patients consisted of a
midline laparotomy through the old incision with mobili-
zation of the adhesions to the undersurface of the fascia
circumferentially. Old mesh, if present, was removed. Old
jejunostomy tube sites were selectively taken down to
facilitate trans-fascial suture placement. One patient had a
colo-cutaneous fistula, and a concomitant colon resection
was performed with takedown of the fistula. In all patients,
subcutaneous flaps were raised bilaterally until the muscle
fibers of the external oblique were visible laterally. The
fascial edges were trimmed to healthy tissue and the hernia
sac excised. The fascial edges were approximated in the
midline and tension assessed. If any significant tension was
present, a bilateral external oblique component separation
was performed as described by Ramirez et al. [6]. Trans-
fascial 0 proline sutures were placed lateral to the site of
the component separation and 3 knots were placed to
prevent any bowel from becoming trapped in the loop of
the suture. After circumferential trans-fascial suture
placement, the midline was closed with figure-of-eight 0
proline suture. The ends of the midline closure sutures were
not cut and the needles left attached. Once the midline was
closed, an appropriately sized non-cross-linked porcine
dermal biologic mesh was selected (XenMatrix in all but
1 patient), trimmed to fit, and placed as an onlay. The
inferior and left lateral trans-fascial sutures were placed
through the mesh using the native swedged on needle and a
free needle for the other end of the suture to create a
mattress stitch through the mesh. After several sutures were
placed on the left side of the mesh, it was pulled firmly
toward the right side, and the right lateral trans-fascial
sutures were placed in similar fashion. Before going back
to place more left lateral trans-fascial sutures, the midline
closure suture ends were brought through the mid-portion
of the mesh, similar to how the trans-fascial sutures were
placed, and tied to secure the middle of the mesh to the
fascia. This sequence continued until all the trans-fascial
sutures and all the midline sutures were brought through
the mesh and tied (Fig. 1). The goal was to place as much
tension as possible on the mesh and relieve tension on
the midline closure. Two closed-suction Jackson–Pratt
drains were placed, one under each flap, and the deep
Fig. 1 Completed repair of large ventral hernia. The fascia has been
closed in the midline after bilateral external oblique component
separations. A 19 9 29 sheet of XenMatrix has been secured in place
with #1 proline mattress sutures placed trans-fascially through the
mesh circumferentially. Note the trans-fascial sutures are placed
lateral to the site of the component separation and the mesh covers
this area bilaterally. The midline figure-of-eight proline sutures have
also been brought through the mesh to anchor the mesh to the fascia in
the midline. The defect was so large that 2 pieces of mesh had to be
used and were sewn together. Note the tautness of the mesh. Tension
is deliberately placed on the mesh to minimize tension on the midline
fascial closure during early healing. The space will be drained with
two #10 Jackson-Pratt drains, the deep subcutaneous tissues sewn
together and attached to the mesh with 2–0 vicryl, and the skin closed
with staples to complete the procedure
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subcutaneous tissues were sutured together and to the mesh
with 2–0 vicryl. The umbilicus was tacked down to the
mesh with 2–0 vicryl sutures since in all cases it was
mobilized off the fascia to facilitate mesh placement cir-
cumferentially over the primary midline closure. A binder
was applied in the operating room, and an epidural catheter
was used for pain control. Patients were typically dis-
charged with the JP drains in place with instructions to
record the outputs. Drains were removed in the clinic when
the output dropped to under 15 cc per day. Patients were
restricted to lifting no more than 5 pounds for 3 months
after the repair.
Statistics
Values are presented as median and interquartile range
unless otherwise specified.
Results
During the three years of the study, 22 patients had repair
of a complex ventral hernia that included use of a non-
cross-linked porcine biologic mesh. Characteristics of the
patients are shown in Table 1. The majority of the patients
were men, had hernia grade 3 or 4, and developed the
ventral hernia after an esophagectomy or gastrectomy for
cancer. The non-cross-linked porcine biologic mesh was
placed as an onlay after primary midline fascial closure in
21 patients and as a bridge in 1 patient with loss of
domain. A concomitant bilateral external oblique compo-
nent separation was performed in 16 patients (73 %).
There was one perioperative death at 5 days from a
myocardial infarction. Complications are shown in
Table 2. The median hospital stay was 7 days and 86 % of
patients left the hospital with one or more closed-suction
drains in place. Two patients, both with multiple medical
comorbidities, developed a wound infection, one superfi-
cial and one with exposure of the mesh. Both were treated
successfully with a wound vac. A seroma was seen by CT
scan in 9 patients (42 %), but required drainage in only 6
patients (27 %). All seromas were treated successfully
with a pig-tail drain placed by ultrasound or CT guidance
(single pig-tail in 5 patients and 2 in one patient) (Fig. 2a,
b). The median time until all drains were removed was
30 days (range 6–211 days). One patient, on steroids for
lung disease, developed a Spigelian hernia 9 months
postoperatively at the site of a trans-fascial suture that had
pulled through the abdominal wall (Fig. 3a, b). This was
repaired laparoscopically.
The median follow-up was 7 months (IQR 2–14 months)
in all patients and exceeded 1 year in 7 patients. Follow-up
included at least one abdominal CT scan in 15 patients
(71 %). Serial CT scans out to 18 months in one patient
showed some residual mesh in place. The only hernia
recurrence was in the patient that was bridged for loss of
domain. His operation was to be staged with a planned
reoperation and primary fascial closure after 3 months, but
the patient did not re-present until over a year later at
which time a recurrent hernia was identified on abdominal
CT scan. At reoperation 19 months after implantation, the
biologic mesh was still partially present and was composed
of 2 layers (Fig. 4a, b). The outer layer was firmly incor-
porated into the subcutaneous tissue, while the inner layer
was adhered to the omentum and colon. The patient
was bridged again, this time with a synthetic mesh, for
continued loss of domain. Another patient underwent
re-exploration for cancer recurrence 4 months after
abdominal wall reconstruction with a XenMatrix onlay.
There was complete incorporation of the subcutaneous
flaps with the mesh, and histology showed extensive neo-
vascularity and fibroblast infiltration into the mesh
(Fig. 5a–c).
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Discussion
Mesh has been used to reinforce repair of a ventral hernia
since the early 1900s. The initial materials included silver,
tantalum gauze, and stainless steel [7]. However, the
introduction of Marlex in 1959 revolutionized hernia repair
and was the foundation for a variety of subsequent syn-
thetic mesh materials and designs. While the use of
Fig. 2 Slices from an abdominal CT scan showing a large seroma above mesh with portion of mesh in fluid, and b resolution of seroma and
intact hernia repair after pig-tail drainage. The mesh is still visible above the fascial closure
Fig. 3 a Abdominal CT scan and b laparoscopic picture of Spigelian
hernia in site where a trans-fascial suture had pulled through the
abdominal wall in a patient on large doses of steroids for lung disease
that had ventral hernia repair. Note the mesh is still visible on the CT
scan after almost a year, and the ventral hernia repair is intact
Fig. 4 Reoperation 19 months after bridging a patient with loss of
domain with XenMatrix. a The mesh has developed into two layers
with the subcutaneous tissues incorporated into the superficial part of
the mesh. The deeper portion of the mesh is against the viscera. The
site of the hernia is just below the retractor where the mesh has
separated from the fascia. Note the absence of any form of
reconstructed abdominal wall. b The deeper portion of mesh has
been separated laterally from the fascia and is being held up by
clamps. Neovascularity and adhesions of the omentum and colon to
the mesh are visible. The mesh with attached viscera was tucked into
the abdomen with no effort to remove it, and since the patient
continued to have loss of domain he was bridged with synthetic mesh
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synthetic mesh has been proven to reduce recurrence, it is
important to recognize that although synthetic mesh is
permanent, the use of synthetic mesh does not mean per-
manent repair of a ventral hernia. Long-term follow-up of a
randomized controlled trial showed that by 10 years, 32 %
of patients that had a ventral hernia repair with proline or
Marlex mesh had developed a recurrent hernia [8]. Further,
the use of synthetic mesh is associated with complications
including shrinkage of the mesh with subsequent chronic
pain and/or hernia recurrence, erosion, and fistula forma-
tion. When placed intra-abdominally, synthetic mesh can
lead to severe adhesions to the viscera, making reoperation
difficult and increasing the risk for enterotomies. Synthetic
mesh is also associated with a risk for both early and
delayed infection, and once infected, synthetic mesh often
needs to be removed. Infected mesh is also a leading cause
of hernia recurrence [9, 10]. In a recent review of 33,832
procedures, Choi et al. [2] reported that the use of mesh in
clean–contaminated cases was associated with a signifi-
cantly increased risk of superficial, deep and organ/space
infections, wound disruption, pneumonia, and sepsis com-
pared to non-use of mesh. Based on these findings, the
authors recommended that synthetic mesh should not be
used in clean–contaminated or contaminated ventral hernia
repairs.
In contrast to synthetic mesh, biologic mesh is not asso-
ciated with a significant risk of erosion or fistula formation
and is likely less susceptible to contamination. In a rat study,
Harth et al. [11] showed that while inoculation of synthetic
mesh with Staphylococcus aureus was never cleared, the
majority of inoculated biologic meshes were culture nega-
tive when explanted, particularly non-cross-linked porcine
dermal grafts. As a consequence of this benefit, the ventral
hernia working group [5] recommended that a biologic mesh
be considered for Hernia Grades 2 and higher. In a recent
review of mesh types, Shankaran et al. [7] listed the char-
acteristics of an ideal mesh and noted that the only mesh
type to fulfill all of the criteria was biologic mesh. The
concept of a biologic mesh is that it is an acellular collagen
matrix that allows neovascularity and ingrowth by native
fibroblasts, with gradual incorporation and replacement of
the mesh by host tissue. Current biologic meshes come from
human dermis and several animal types and tissues. The
biologic mesh can be cross-linked or non-cross-linked, but
non-cross-linked mesh incorporates more reliably and is
currently preferred in many centers [12].
The biologic mesh types that have been reported for
ventral hernia repair include porcine submucosa, human
dermis, and porcine dermis. The use of porcine submucosa
(Surgisis; Cook Surgical, Bloomington, IN) for ventral
hernia repair was associated with a 41 % complication rate













Fig. 5 Re-exploration at 4 months in a patient with cancer. a A full-
thickness resection of subcutaneous tissue, XenMatrix mesh, and
native abdominal wall (at site of arrow) for histology. Note the
incorporation of the subcutaneous tissue (SQ) into the mesh (XM),
and the mesh to the abdominal wall (AW). b Histology showing
neovascularity going entirely through the mesh from the abdominal
wall to the subcutaneous tissue (arrow). c Higher magnification
showing infiltration of fibroblasts into the open collagen structure of
the mesh (XM)
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caution with this mesh, particularly in critically ill patients
and those with dirty wounds. In another study, Surgisis was
compared to Alloderm (LifeCell Corp, Branchburg, NJ) for
ventral hernia repair, and the authors reported a high
incidence of seroma formation and abdominal discomfort
related to poor tissue integration with Surgisis, and dias-
tasis and hernia recurrence with Alloderm related to
stretching of the graft [14]. Other studies have confirmed
that since Alloderm increases in length by 30–50 % when
placed under tension due to the elastin fibers in the graft,
there is a high incidence of laxity in the abdominal wall
and hernia recurrence, particularly when it is used to bridge
a fascial defect [15, 16]. In a direct comparison of Allo-
derm versus soft polypropylene mesh as an underlay in
clean cases, Ko et al. [17] reported a significantly higher
recurrence rate with Alloderm (61 %) compared to the
synthetic mesh (12 %). Finally, in a review of published
literature on biologic mesh use for hernia repair, Hiles et al.
[18] concluded that Alloderm was associated with the
highest failure rate with the shortest average follow-up of
all the materials.
Given the poor results with Surgisis and Alloderm,
interest has shifted to the use of non-cross-linked porcine
dermis as a biologic mesh for ventral hernia repair. The
two available grafts are XenMatrix (Davol, Warwick RI)
and Strattice (LifeCell Corp, Branchburg, NJ). Pomahac
et al. [19] reported on the use of XenMatrix as a subfascial
underlay in 16 patients. Seromas developed in 21 % and
there was one recurrent hernia (7 %) at a mean follow-up
of 16.5 months. In an expansion of that series, the authors
recently reported on 40 patients, 32 with primary fascial
closure, at a mean follow-up of 40.1 months [20]. A ser-
oma developed in 21 % of patients, and the XenMatrix was
removed in 1 patient for infection when it was used to
reconstruct the abdominal wall after removal of infected
synthetic mesh. The hernia recurrence rate remained at
7.6 %. In another study, Byrnes et al. [21] used XenMatrix
as an underlay (84 %) or bridge (16 %) repair in 57
patients. They identified 4 recurrences (7.2 %) at a mean
follow-up of 30.6 months, but noted that all recurrences
were within 3 weeks of the repair and all were in patients
that were bridged. There have been three reports on the use
of Strattice for ventral hernia repair and one case series of
three patients [22–25]. Rosen et al. [22] reported on a small
group of 12 patients with combined ventral and parastomal
hernias repaired with a retrorectus technique using Strattice
mesh. Postoperative complications occurred in 33 % of
patients, and at a mean follow-up of 14 months a hernia
recurred in two patients. In a larger series of 80 patients
with infected or contaminated ventral hernias, Rosen et al.
[23] noted a 30 % recurrence rate with Strattice mesh at
one year with intraperitoneal repair and a 20 % recurrence
when the mesh was used as a sublay after primary closure
and component separation. Lastly, Patel et al. [24] reported
on 41 patients that had primary fascial closure with Strat-
tice underlay and component separation in nearly everyone.
Complications occurred in 24 % of patients and were lar-
gely related to skin necrosis. At a mean follow-up of
1.3 years they reported no recurrent hernias.
In this series, we used XenMatrix as an onlay for rein-
forcement of ventral hernia repair. We deliberately placed
as much tension as possible on the mesh to minimize ten-
sion on the primary midline fascial closure and made liberal
use of an external oblique component separation to further
reduce tension. A seroma requiring intervention developed
in 27 % of patients, but all were successfully treated by pig-
tail catheter drainage. No patient had flap necrosis. No mesh
was removed for infection despite the fact that 77 % of
patients were classified as having hernia grades 3 or 4, and
the wound was clean–contaminated or contaminated in
32 % of patients. Based on the recommendations of Choi
et al. [2], synthetic mesh use would have been contraindi-
cated in these patients given the significantly increased risk
of infection. The only hernia recurrence was in a patient that
was bridged as a planned staged procedure for loss of
domain, but the patient failed to present for the second stage
of the repair until 19 months later. None of the patients that
had primary fascial closure and XenMatrix onlay have
developed a recurrent hernia, including 7 patients with a
minimum of 12 months of follow-up.
We recognize that this is a small series with short
overall follow-up. However, there are several factors that
make this study unique. For one, this is the first study to
report the use of XenMatrix or any non-cross-linked por-
cine dermal graft as an onlay for ventral hernia repair. Most
centers consider the Rives-Stoppa repair with sublay of the
mesh below the rectus to be the gold standard for ventral
hernia repair. Part of the rationale for this approach is to
keep the mesh as deep as possible to avoid contamination
should there be a superficial wound infection. However, the
use of a biologic mesh changes this concern since exposure
of a biologic mesh to a superficial wound infection does not
have the same implications as a synthetic mesh. In our
series, there were two patients with superficial wound
infections, one with exposed mesh, and both healed with
wound vac treatment. No mesh was removed for infection.
From the standpoint of hernia recurrence, there is little data
to suggest that sublay is superior to an onlay. In 2011, a
Cochrane review was published comparing onlay and
sublay mesh for ventral hernia repair. The operative times
were shorter with a synthetic mesh onlay but hospital stay,
surgical pain, overall complication rate, and hernia recur-
rence rate were similar for the onlay and sublay technique
[26]. In our experience, the onlay technique allowed for the
prompt addition of an external oblique component sepa-
ration if deemed necessary since bilateral subcutaneous
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flaps had already been raised. In our opinion, the sub-
stantial increase in abdominal wall movement that
accompanies this release makes it an important addition in
any patient with even mild tension on the midline closure.
The most common morbidity we encountered was ser-
oma formation, likely as a host response to the biologic
mesh since our incidence was higher than reports in the
literature for synthetic mesh onlay (23 %) and in compar-
ison with our own historical data (7.1 %, unpublished data)
[27]. This experience has led us to consider the use of
aerosolized talc in the space beneath the subcutaneous flaps
given recent evidence showing a significant reduction in
seroma formation, length of indwelling drains, and cellu-
litis with the use of talc [28]. However, it is important to
realize that a seroma in a patient with a biologic mesh is
completely different than a seroma in a patient with a
synthetic mesh. The same level of concern regarding
introducing infection with drainage of a seroma is not there
with a biologic mesh compared to a synthetic mesh, and
some of the pig-tail catheters we placed to drain a seroma
stayed for several weeks with no infectious complications.
Therefore, while a seroma was common in our series, pig-
tail catheter drainage was easy, successfully resolved the
seroma in all patients, and was not associated with any
complications.
Another unique aspect of our study is that most of the
patients had cancer and developed the ventral hernia after an
esophagectomy or gastrectomy for their disease. Many of
these patients had received neoadjuvant chemotherapy or
chemoradiotherapy shortly before resection and likely had
impaired wound healing at their original operation. At the
time of ventral hernia repair, most were still in active follow-
up for their cancer and at risk for recurrence. Consequently,
we had reservations about placement of a synthetic mesh
which, if it became infected, could hamper chemotherapy or
treatment of a recurrence. Most of our patients were getting
routine CT scans as part of their cancer follow-up, which
allowed us to observe the natural history of the XenMatrix
onlay at 3–6 month intervals after placement. We observed
that the mesh was still visible by CT in a patient at
18 months postoperatively, suggesting that the time to full
integration of the XenMatrix mesh exceeds 12 months.
Further support for this timeline comes from our re-opera-
tion 19 months after placing XenMatrix as a bridge for loss
of domain in a patient. At reoperation, the mesh was still
present, although it had separated into two layers with the
superficial portion incorporated into the subcutaneous tis-
sues and the deep portion adherent to the omentum and
abdominal viscera. There was a recurrent hernia at the
inferior portion of the mesh, but the mesh was still present
over 1.5 years later. Importantly, there was no reconstructed
abdominal wall when the mesh was used as a bridge, and
similar to what other reports have shown, our findings
confirm that if a biologic mesh is used as a bridge, then there
will be a recurrent hernia [21]. In contrast, when the
XenMatrix was used as an onlay over primary fascial closure,
we found evidence for ‘‘proof of concept’’ of a biologic mesh
in the patient that we re-explored for cancer at 4 months
postimplant. Histologically, there was neovascularity going
completely through the mesh into the subcutaneous tissue and
evidence of fibroblast ingrowth into the mesh.
Our concept for ventral hernia repair with a biologic
mesh is that the tension should be placed on the mesh and
taken off of the primary midline fascial closure, rather than
just laying the mesh over the midline closure as a buttress.
The use of the lateral trans-fascial sutures allows signifi-
cant tension to be placed on the mesh, and the onlay
position of the mesh allows the midline to be closed and the
amount of tension being placed on the mesh adjusted as the
trans-fascial sutures are placed and tied. As the biologic
mesh incorporates, tension is gradually transitioned to the
native tissues. The importance of tension in wound healing
has been studied by Culbertson et al. [29] who suggested
that incisional abdominal hernias develop from early
wound separation and failure, often within the first month,
related to factors such as closure technique, wound ische-
mia, tension, or comorbid conditions that impair wound
healing. However, they showed in a model of cultured
fibroblasts that some tension is important to stimulate
proliferation and orientation of fibroblasts and for collagen
contraction [29]. This fits with our concept that gradual
application of tension to the midline closure allows for
initial secure healing and then subsequent strengthening as
the native tissues assume more of the load during biologic
mesh incorporation and replacement. Future studies and
longer term follow-up will allow assessment of the role for
and potential benefits of biologic XenMatrix mesh onlay
for ventral hernia repair.
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